Helix Biopharma (OTCMKTS:HBPCF – Get Free Report) released its earnings results on Friday. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.07, Zacks reports.
Helix Biopharma Price Performance
Shares of HBPCF stock remained flat at $1.71 on Friday. The stock has a market cap of $130.61 million, a price-to-earnings ratio of -34.20 and a beta of 0.17. The stock’s 50-day moving average price is $1.72 and its 200-day moving average price is $1.73. Helix Biopharma has a fifty-two week low of $1.71 and a fifty-two week high of $1.73.
About Helix Biopharma
Helix BioPharma Corp is a clinical‐stage biotechnology company focused on the research, development and commercialization of immunotherapeutic drug candidates for oncology and rare disease indications. Headquartered in Laval, Quebec, the company leverages proprietary platforms designed to activate or modulate the immune system, with programs spanning small‐molecule immunoconjugates and biologic modalities. Its lead candidate, L-DOS47, is an antibody‐based immunoconjugate in clinical evaluation for non–small cell lung cancer, and Helix maintains additional discovery‐stage assets targeting solid tumors and hematological malignancies.
Founded in 1983, Helix BioPharma has built a global network of collaborations with academic research centers and contract research organizations across North America and Europe.
Featured Articles
- Five stocks we like better than Helix Biopharma
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for Helix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
